title: Neoadjuvant Endocrine Therapy in Breast Cancer.
abstract: Women who suffer from large or locally advanced malignant breast tumors are now commonly treated with preoperative ('neoadjuvant') systemic therapy to improve surgical outcomes and to raise the chances for breast-conserving therapy (BCT). Until recently, chemotherapy was the treatment of choice, and primary systemic endocrine treatment was restricted to medically frail or older women with receptor-positive breast cancer. The development of modern aromatase inhibitors (Als) and their subsequent clinical evaluation in neoadjuvant trials now provides us with an alternative to chemotherapy that is thought to be equally effective, yet considerably better tolerated. Several large prospective trials have compared tamoxifen with the non-steroidal AIs letrozole and anastrozole and the steroidal Al exemestane, with improved outcomes for all AIs in terms of tumor remission and rate of BCT. A number of predictive biomarkers now also allow us to identify those tumors that most likely respond to a certain endocrine regimen.
authors.affiliation: Division of Special Gynecology, Department of OB/GYN, Medical University of Vienna, Austria.
authors.forename: Christian F
authors.initials: CF
authors.lastname: Singer
references.citation: Breast Cancer Res Treat. 2008 Nov;112(1):203-13
references.pmid: 18158620
references.citation: Br J Surg. 1991 May;78(5):591-4
references.pmid: 2059815
references.citation: Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8715-21
references.pmid: 16361558
references.citation: Breast Cancer Res Treat. 2008 Jan;107(1):87-94
references.pmid: 18043897
references.citation: Cancer. 2007 Jul 15;110(2):244-54
references.pmid: 17538978
references.citation: Clin Cancer Res. 2004 Oct 1;10(19):6622-8
references.pmid: 15475452
references.citation: Eur J Surg Oncol. 1994 Jun;20(3):207-14
references.pmid: 8181594
references.citation: Ann Oncol. 2003 Mar;14(3):414-20
references.pmid: 12598347
references.citation: Br J Surg. 1992 Dec;79(12):1317-20
references.pmid: 1486428
references.citation: J Clin Oncol. 2003 Nov 15;21(22):4165-74
references.pmid: 14559892
references.citation: Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):951s-8s
references.pmid: 15701892
references.citation: J Natl Cancer Inst. 1995 May 17;87(10):746-50
references.pmid: 7563152
references.citation: Oncology. 2003;64(4):289-99
references.pmid: 12759523
references.citation: Br J Surg. 2004 Jun;91(6):699-704
references.pmid: 15164437
references.citation: Mol Cell Endocrinol. 2005 Jul 15;239(1-2):27-36
references.pmid: 15950373
references.citation: Cancer Control. 2002 Mar-Apr;9(2 Suppl):9-15
references.pmid: 11965226
references.citation: Oncologist. 2007 Jul;12(7):774-84
references.pmid: 17673609
references.citation: J Clin Oncol. 2001 Sep 15;19(18):3808-16
references.pmid: 11559718
references.citation: Ann Oncol. 2001 Nov;12(11):1527-32
references.pmid: 11822750